Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT05768945
Status
Completed

Conditions

  • Diabetes

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide claim is used as the exposure group.
  • DPP-4 inhibitor — DRUG
    DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.

Study Details

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Key Dates

Start date
Nov 30, 2022
Status verified
Oct 2025
Primary completion
Jul 7, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
742,670 participants (actual)

Arms

  • Arm: Semaglutide
    Exposure group
  • Arm: DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin)
    Reference group

Primary Outcome Measure

Time to Dementia Onset [ Time Frame: Median follow up times: 1) 98 days (exp), 134 days (ref) 2) 118 days (exp), 132 days (ref) 3) 90 days (exp), 308 days (ref) 4) 99 days (exp), 135 days (ref) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115-

Related coverage on Hipa.ai

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies